Department of Biology, University of Texas at San Antonio, TX 78249, USA.
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA.
Cell Immunol. 2019 May;339:10-23. doi: 10.1016/j.cellimm.2018.10.006. Epub 2018 Oct 21.
While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab (RTX), a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated: B cells. This has been reaffirmed by results from clinical trials testing the efficacy of subsequently developed B cell-depleting mAbs targeting CD20 as well as studies revisiting the effects of previous disease-modifying therapies (DMTs) on B cell subsets thought to modulate disease severity. In this review, we summarize current knowledge regarding the complex roles of B cells in MS pathogenesis and current and potential future B cell-directed therapies.
虽然长期以来人们一直认为 T 细胞是多发性硬化症 (MS) 发病机制的主要介质，但利妥昔单抗（RTX）治疗的疗效观察表明，B 细胞是 MS 的一个此前被低估的关键贡献者，RTX 是一种针对 CD20 的单克隆抗体。随后针对 CD20 的 B 细胞耗竭单克隆抗体的临床试验结果以及重新研究先前改变疾病疗法 (DMT) 对被认为调节疾病严重程度的 B 细胞亚群的影响的研究进一步证实了这一点。在这篇综述中，我们总结了目前关于 B 细胞在 MS 发病机制中的复杂作用以及当前和潜在的未来 B 细胞靶向治疗的知识。
